Abstract
Moclobemide is a reversible inhibitor of the monoamine oxidase type A. In clinical studies, more than 3900 patients have been treated with moclobemide for depression. Eighteen of these patients attempted suicide by overdosing moclobemide with or without other drugs. All patients recovered fully without leaving signs of cardio-or hepatotoxicity. Moclobemide can safely be prescribed for in- and out-patient treatment of depression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl 28:21–31
Cassidy S, Henry J (1987) Fatal toxicity of antidepressant drugs in overdose. Br Med J 295:1021–1024
Da Prada M et al. (1989) Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl 28:5–20
Pöldinger W (1987) Incidence and evaluation of risk of suicide in depression. In: Bizière K, Garratini S, Simon P (eds) Proceedings of Symposium ‘Quo vadis?’: diagnosis and treatment of depression, May 11–12, 1987, Montpellier, France
Versiani M et al. (1990) Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand Suppl 82:29–34
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hetzel, W. Safety of moclobemide taken in overdose for attempted suicide. Psychopharmacology 106 (Suppl 1), S127–S129 (1992). https://doi.org/10.1007/BF02246256
Issue Date:
DOI: https://doi.org/10.1007/BF02246256